List of Excipients in Branded Drug TESSALON

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pfizer Laboratories Div Pfizer Inc	TESSALON	benzonatate	0069-0122	D&C YELLOW NO. 10
Pfizer Laboratories Div Pfizer Inc	TESSALON	benzonatate	0069-0122	GELATIN
Pfizer Laboratories Div Pfizer Inc	TESSALON	benzonatate	0069-0122	GLYCERIN

Tessalon Excipient Strategy and Commercial Opportunities for Benzonatate Capsules

Last updated: August 30, 2026

Tessalon is a prescription benzonatate product for symptomatic relief of cough. Its commercial value is no longer protected by meaningful active-ingredient exclusivity. The strongest opportunities are formulation execution, capsule safety, packaging, excipient differentiation, and reliable generic supply. The central technical constraint is that benzonatate capsules must be swallowed whole because chewing or dissolving the capsule can cause oral and pharyngeal anesthesia, choking, and potentially fatal overdose, particularly in children [1].

What is Tessalon and how is it formulated?

Tessalon contains benzonatate, a nonnarcotic antitussive related chemically to local anesthetics. The product is marketed in 100-mg and 200-mg liquid-filled capsules. The labeled inactive ingredients include gelatin, glycerin, sorbitol, methylparaben, propylparaben, D&C Yellow No. 10, and FD&C Yellow No. 6, although the exact presentation and labeling should be confirmed against the current FDA-approved package insert [1].

Attribute	Tessalon profile
Active ingredient	Benzonatate
Therapeutic class	Antitussive
Dosage form	Oral liquid-filled capsule
Strengths	100 mg and 200 mg
Route	Oral
Administration constraint	Capsule must be swallowed whole
Key safety issue	Oral numbness, choking, laryngospasm, and overdose if chewed or sucked
Prescription status	FDA-approved prescription product
Generic competition	Multiple generic benzonatate capsules
Primary commercial barrier	Safety-sensitive dosage form and generic price competition

The excipient system supports a liquid-filled gelatin capsule rather than a conventional compressed tablet. Glycerin and sorbitol function primarily as plasticizing or fill-system components, while methylparaben and propylparaben provide preservative functionality. Gelatin supplies the capsule shell. The colorants provide product identification but create an opportunity for color-free or lower-color alternatives.

What excipients are used in Tessalon capsules?

Tessalon’s listed excipients support five formulation objectives: capsule flexibility, liquid-fill compatibility, microbial control, visual identification, and manufacturability.

Gelatin and capsule-shell performance

Gelatin provides a mature, low-cost shell platform with extensive manufacturing infrastructure. Its disadvantages include animal origin, potential religious or dietary restrictions, sensitivity to humidity, and possible cross-linking or dissolution changes during storage.

A generic or reformulated product could evaluate:

• Fish gelatin or modified gelatin for selected markets.
• Hypromellose capsules where the fill technology is compatible.
• Other non-gelatin shell systems.
• Lower-moisture packaging to protect shell integrity.
• Barrier blisters or high-protection bottles.

A shell substitution would require more than a cosmetic change. The sponsor would need to evaluate capsule brittleness, leakage, oxygen and moisture transmission, dissolution, mechanical robustness, and stability across climatic zones.

Glycerin, sorbitol, and fill rheology

Glycerin and sorbitol help maintain a flexible capsule shell and support the physical properties of the liquid fill. Changes in their concentrations can affect:

• Fill viscosity.
• Capsule seam integrity.
• Leakage during storage.
• Shell brittleness.
• Drug release.
• Water activity.
• Manufacturing throughput.

A lower-sugar or sugar-free positioning requires careful review because sorbitol may have gastrointestinal tolerability implications at higher exposure, while polyol substitution can change fill density and capsule dimensions. Any reformulation should preserve dose uniformity and release performance.

Parabens and preservative strategy

Methylparaben and propylparaben are conventional preservatives. A preservative-free liquid fill could have commercial appeal, particularly for consumers seeking simpler ingredient profiles, but the product would need a validated microbiological control strategy. Options could include:

• A lower-water or nonaqueous fill.
• Alternative preservative systems.
• Improved manufacturing controls.
• Single-dose packaging.
• A capsule shell and fill combination with lower microbial risk.

Preservative changes can trigger extractables and leachables, compatibility, stability, and labeling work. A preservative-free claim would be commercially useful only if it is supported by a stable, scalable manufacturing process.

Colorants and product identification

Tessalon uses yellow colorants for visual differentiation. A color-free capsule could address consumer concerns about synthetic dyes and simplify certain market-specific excipient requirements. The tradeoff is a potential increase in look-alike risk, especially where 100-mg and 200-mg products are sold in similar packaging.

A stronger strategy would combine color reduction with:

• Distinct capsule dimensions.
• Imprinted strength identifiers.
• Unit-dose blister packaging.
• High-contrast labeling.
• Separate 100-mg and 200-mg carton designs.

What formulation patents protect Tessalon?

Tessalon’s active-ingredient patent protection is long expired. Benzonatate has been marketed for decades, and generic benzonatate products are approved in the United States. The current commercial issue is therefore not a conventional new-drug patent moat.

The relevant intellectual-property categories are narrower:

IP category	Strategic relevance
Original benzonatate composition patents	Expired or commercially obsolete
Capsule-shell composition	Potentially protectable, but generally difficult to make broad
Liquid-fill formulation	May support narrow formulation claims
Manufacturing process	Can protect process parameters and quality controls
Packaging and dispensing system	May support device or packaging claims
Abuse-deterrent or child-resistant presentation	Potential commercial differentiation
Method of use	Limited value for ordinary cough treatment absent a genuinely novel indication

The Orange Book should be reviewed for the current reference-listed drug and any listed patents before a launch decision. Because generic benzonatate products are already marketed, there is no apparent basis to assume that an active Orange Book patent blocks ordinary generic entry [2].

When does Tessalon lose exclusivity?

Tessalon has already lost practical market exclusivity. The product’s original regulatory and patent protections are historic, and generic benzonatate capsules are available.

Exclusivity factor	Current assessment
New chemical entity exclusivity	Expired
Original patent protection	Expired
Pediatric exclusivity	No current commercial relevance
Orphan exclusivity	Not applicable to ordinary cough treatment
Reference-product exclusivity	No meaningful current barrier to generic entry
Generic entry	Established
Biosimilar risk	Not applicable

The competitive question is not whether generic entry will occur. It is whether a differentiated product can earn a price premium over low-cost benzonatate capsules.

What FDA regulatory status applies to Tessalon and generic benzonatate?

Tessalon is an FDA-approved prescription oral capsule. Generic benzonatate products are generally submitted through abbreviated new drug applications, with approval based primarily on pharmaceutical equivalence and bioequivalence rather than a new clinical efficacy program [3].

A reformulated product would face different regulatory burdens depending on the extent of change:

Product change	Likely regulatory focus
Same API, strength, and dosage form with excipient changes	Pharmaceutical equivalence, bioequivalence, stability, quality
New gelatin-free shell	Dissolution, stability, shell performance, bioequivalence
New liquid-fill system	Drug release, content uniformity, viscosity, stability
New strength	Dose proportionality or additional bioequivalence work
New abuse-deterrent presentation	Additional in vitro, human factors, and possibly clinical evidence
New indication	Full clinical development and regulatory strategy
Pediatric-oriented product	Enhanced safety, packaging, and labeling review

FDA’s post-approval change framework classifies formulation and manufacturing changes according to their potential effect on product quality. A sponsor should not assume that an excipient substitution is administratively minor. Liquid-filled capsule systems can be sensitive to changes in moisture, viscosity, preservative concentration, and shell composition [4].

What excipient strategy offers the strongest commercial opportunity?

The most defensible strategy is a safety-led reformulation rather than a simple “clean label” product.

1. Child-resistant and unit-dose packaging

Benzonatate carries a specific pediatric hazard. Accidental ingestion of small quantities has been associated with severe toxicity and death in children under 10 years old [1]. Unit-dose, child-resistant blister packaging could reduce access to multiple capsules and improve dose tracking.

Potential commercial claims include:

• Child-resistant packaging.
• Unit-dose protection.
• Senior-friendly opening after validated human-factors testing.
• Improved travel stability.
• Reduced medication mix-ups.

Packaging claims may provide more practical differentiation than changing a low-cost excipient.

2. Gelatin-free capsules

A gelatin-free product could address vegetarian, religious, dietary, and market-access requirements. Hypromellose or another alternative shell could support premium positioning, but the formulation would need to demonstrate acceptable shell-fill compatibility and long-term stability.

This opportunity is strongest in markets where gelatin avoidance affects purchasing decisions. It is weaker in highly price-sensitive U.S. generic channels unless paired with supply reliability or retail differentiation.

3. Dye-free capsules

Dye-free Tessalon alternatives could appeal to consumers, pharmacists, and health systems seeking fewer synthetic colorants. The commercial benefit would be modest unless supported by clear packaging differentiation and broad pharmacy distribution.

4. Preservative-free formulation

A preservative-free capsule could create a more meaningful product story, but its value depends on whether the product can maintain microbiological quality without introducing a more complex manufacturing process. In a dry or low-water liquid-fill system, this may be feasible. A sponsor would need to prove stability, microbial control, and capsule compatibility.

5. Improved identification of 100-mg and 200-mg strengths

Strength confusion is a practical risk when both products use similar capsule colors and packaging. A differentiated imprint, contrasting shell design, or strength-specific blister could improve dispensing accuracy without materially changing the formulation.

How strong is the Tessalon patent estate?

The estate is weak as a barrier to ordinary generic competition. The principal opportunities for new patent filings would involve narrow, technically supported claims directed to:

• A specific benzonatate liquid-fill composition.
• Defined viscosity or dissolution parameters.
• A non-gelatin capsule with demonstrated stability.
• A preservative-free formulation.
• A moisture-barrier package that preserves shell integrity.
• A child-resistant dispensing system.
• A validated abuse-deterrent or misuse-resistant dosage form.

Broad claims covering “benzonatate in a capsule with excipients” would face substantial validity and obviousness risk because the active ingredient and capsule dosage form are longstanding. Stronger protection would require unexpected stability, release, safety, or manufacturing results.

Trade-secret protection may be more valuable for fill-process controls, shell conditioning, equipment settings, and quality-control methods that are difficult to reverse engineer.

What patent litigation and Paragraph IV risks affect benzonatate?

Benzonatate has established generic competition, so the principal Paragraph IV event occurred historically during the initial generic-entry period rather than representing a current market-opening event. A new generic applicant would face ordinary patent certification analysis, but the commercial risk is primarily price erosion and supply competition.

A reformulated product could create new litigation exposure if it asserts narrow formulation or packaging patents against later entrants. The sponsor would need to balance litigation value against the limited revenue available in a mature cough market.

No biosimilar risk applies because benzonatate is a small-molecule drug, not a biologic. The relevant competitors are generic capsule manufacturers and potentially branded or over-the-counter cough products.

How does Tessalon compare with competing cough products?

Product category	Active ingredient	Dosage-form opportunity	Main commercial issue
Tessalon and generic benzonatate	Benzonatate	Liquid-filled capsule	Low-cost generic competition; swallowing safety
Dextromethorphan products	Dextromethorphan	Syrup, lozenge, tablet, capsule	Broad OTC competition and abuse concerns
Guaifenesin combinations	Guaifenesin with other actives	Tablet, liquid, extended release	Combination-product differentiation
Codeine-containing products	Codeine combinations	Oral liquid or tablet	Controlled-substance restrictions
Prescription opioid alternatives	Various	Multiple forms	Safety and regulatory constraints

Benzonatate’s differentiation is its nonopioid prescription status and capsule-based delivery. Its weakness is the narrow product experience: the capsule must remain intact, cannot be chewed, and has a serious pediatric ingestion warning.

What generic launch scenarios exist for a new Tessalon formulation?

Low-cost ANDA capsule

This approach offers the fastest route to market if the formulation is pharmaceutically equivalent and bioequivalent. It has the lowest development cost but also the weakest pricing power.

Gelatin-free or dye-free capsule

This strategy can support formulary, retail, and specialty-pharmacy differentiation. The premium depends on supply reliability and whether distributors accept the product as a meaningful alternative.

Safety-focused unit-dose product

A unit-dose blister with child-resistant secondary packaging could target institutional, mail-order, and caregiver markets. The product would still compete with cheap capsules, but its commercial proposition would be clearer.

New delivery system

A lozenge, orally disintegrating product, liquid, or other dosage form could improve administration but would create greater regulatory and clinical risk. A noncapsule product may also increase the risk of oral numbness because the label specifically requires swallowing the capsule whole.

What revenue exposure and licensing opportunities exist?

Standalone Tessalon revenue is difficult to isolate because branded and generic benzonatate sales are fragmented across manufacturers and distribution channels. The addressable market is mature and likely price-sensitive. A premium product would need to capture value through a defined customer problem rather than rely on the benzonatate name alone.

Potential licensing opportunities include:

• Non-gelatin soft-capsule technology.
• Low-moisture liquid-fill systems.
• Child-resistant blister platforms.
• Capsule-shell barrier technologies.
• Preservative-free fill technologies.
• Contract manufacturing with established softgel capacity.
• Retail or pharmacy partnerships for differentiated generic products.

The best licensing target is a platform that can be used across multiple mature oral drugs. A technology developed only for benzonatate would face limited return potential unless it materially improves safety or manufacturing yield.

Key Takeaways

• Tessalon is benzonatate in 100-mg and 200-mg liquid-filled capsules.
• Its original patent and exclusivity position no longer provides a meaningful barrier to generic competition.
• The key formulation constraint is the requirement to swallow the capsule whole.
• The strongest opportunities are child-resistant unit-dose packaging, gelatin-free shells, dye-free presentation, and preservative optimization.
• Broad formulation patents would be vulnerable; narrow claims tied to demonstrated technical performance are more credible.
• Biosimilar risk does not apply.
• A low-cost generic launch offers volume but limited margin.
• A premium launch requires a measurable safety, access, ingredient, or packaging advantage.
• Manufacturing know-how and supply reliability may provide more durable value than broad patent claims.

FAQs About Tessalon Excipients and Commercial Strategy

Can benzonatate be reformulated as a tablet?

Yes, a tablet would be technically possible, but the change would create a new dosage-form and bioequivalence strategy. It could also increase the risk of oral contact and numbness if the product is chewed or allowed to dissolve.

Is Tessalon gelatin-free?

The labeled Tessalon capsule formulation uses gelatin. A gelatin-free version would require a different capsule-shell system and supporting stability, dissolution, and bioequivalence data [1].

Does Tessalon contain artificial colors?

The labeled product contains D&C Yellow No. 10 and FD&C Yellow No. 6. A dye-free generic or reformulated product could provide a limited but commercially identifiable differentiation point [1].

Can a company patent a new benzonatate capsule?

A company may be able to patent a narrowly defined capsule, fill composition, manufacturing process, or packaging system. A broad claim covering benzonatate in a conventional capsule would face significant prior-art challenges.

Is there a market for a preservative-free Tessalon product?

There may be a targeted market, particularly among consumers and institutions seeking reduced-excipient formulations. Commercial success would depend on proving microbiological control, stability, capsule compatibility, and a clear price or access advantage.

References

1. DailyMed. (n.d.). Tessalon: Benzonatate capsule, liquid filled, prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application (ANDA): Generics. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda

4. U.S. Food and Drug Administration. (2004). Changes to an approved NDA or ANDA: Guidance for industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/changes-approved-nda-or-anda